Patients in the U.S. now have access to the first generic GLP-1 treatment approved for weight loss as Teva has launched its copycat of Novo Nordisk’s injected Saxenda (liraglutide). The compound, ...

Teva Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration for the first generic GLP-1 medication for weight loss, the Parsippany-based company announced Aug. 28. The ...

This article was reviewed by Darragh O’Carroll, MD. Ozempic Alternatives for Weight Loss Key takeaways: Ozempic® alternatives ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. For the first time, a generic GLP-1 has been approved by ...

Novo Nordisk, which lobbied to win Medicaid reimbursement for its obesity drug Wegovy, is fighting to keep that coverage as ...

The World Health Organisation (WHO) has updated its model list of essential medicines (EML) to include four key obesity and type 2 diabetes (T2D) drugs. This includes Novo Nordisk’s semaglutide, ...

The South Korean government said Monday it plans to tighten regulations on the misuse of medications such as Wegovy and ...

Teva's generic Saxenda is the first generic GLP-1 indicated for weight loss. Richardsen added, “This is the fifth first-to-market entry of a Teva generic this year and is an important addition to Teva ...

As the demand for affordable healthcare options grows, the pharmaceutical industry is increasingly focused on developing generic drugs to expand access and reduce costs. This trend is driving major ...